{'fraction_non_alphanumeric': 0.025691699604743084, 'fraction_numerical': 0.009881422924901186, 'mean_word_length': 4.958823529411765, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rethinking the NHS: Promise and Performance

Comments from Lorex Pharmaceuticals The author makes reference to a carbamazepinediltiazem interaction but it should be noted that this is a kinetic interaction, increasing the blood levels of carbamazepine and sometimes giving rise to the known side effects of this drug. There is no evidence of a pharmacodynamic interaction. The cited published report (ref 8) of a possible diltiazem-induced psychosis seems to contain an element of doubt, since as the author makes clear, a re-challenge was unsuccessful (ref 9). Of the two further patients referenced in the case report, the CNS effects in one case were dose-related, in the other the link to the calcium antagonist seems doubtful: one male patient showed irritability and hallucinations on 480 mg/dose of diltiazem. The symptoms disappeared on reducing the dose to 180 mg/day. The other patient, a 70-year-old male alcoholic had hallucinations while taking diltiazem. These continued after the drug was stopped.